S 1172 IS
106th CONGRESS
1st Session
S. 1172
To provide a patent term restoration review procedure for certain
drug products.
IN THE SENATE OF THE UNITED STATES
May 27, 1999
Mr. TORRICELLI introduced the following bill; which was read twice and
referred to the Committee on the Judiciary
A BILL
To provide a patent term restoration review procedure for certain
drug products.
Be it enacted by the Senate and House of Representatives of the United
States of America in Congress assembled,
SECTION 1. PATENT TERM RESTORATION REVIEW PROCEDURE FOR CERTAIN DRUG
PRODUCTS.
(a) SHORT TITLE- This Act may be cited as the `Drug Patent Term
Restoration Review Procedure Act of 1999'.
(b) PATENT TERM RESTORATION-
(1) IN GENERAL- Chapter 14 of title 35, United States Code, is amended
by inserting after section 155A the following new section:
`Sec. 155B. Patent term restoration review procedure for certain drug
products
`(a) DEFINITIONS- For purposes of this section--
`(1) the term `Commissioner' means the Commissioner of Patents and
Trademarks; and
`(2) the term `drug product' has the meaning given that term under
section 156(f)(2)(A), but does not include drugs or products described under
section 156(f)(2)(B).
`(b) SPECIAL PATENT TERM REVIEW PROCEDURE-
`(A) PATENT RESTORED- The term of any patent described under
subparagraph (B) shall be restored under paragraph (3) from the expiration
date determined under section 154 (including any extension granted under
section 156), if the Commissioner determines that the standards under
paragraph (2) have been met.
`(B) PATENT- Subparagraph (A) refers to any patent that--
`(i) has been extended under section 156, subject to the 2-year
limitation described under section 156(g)(6)(c);
`(II) the date of enactment of this section; and
`(III) the date of filing an application under this section;
and
`(iii) claims a drug product, a method of using a drug product, or a
method of manufacturing a drug product.
`(A) IN GENERAL- Upon application by the owner of record of the patent
or its agent under paragraph (5) and consideration of the application and
all materials submitted by parties that would be aggrieved by grant of the
restoration of a patent, the term of a patent described in paragraph (1)
shall be restored if the Commissioner determines that--
`(i) the period set forth in section 156(g)(1)(B)(ii) for the drug
product exceeded 60 months;
`(ii) the owner of record of the patent or its agent has established
by clear and convincing evidence that the patent owner acted with due
diligence (as such term is defined in section 156(d)(3) and applied in
section 156(d)(2)) during the regulatory review period referred to in
section 156(g)(1)(B); and
`(iii) granting the patent restoration would not be detrimental to
the public interest and the interest of fairness, as defined by the
factors set forth in paragraph (7).
`(i) DEDUCTION OF TIME- If the Commissioner determines there is
substantial evidence that the patent owner did not act with due
diligence during a part of the regulatory review period, that part shall
be deducted from the total amount of time in the applicable regulatory
review period referred to in section 156(g)(1)(B), and the resulting
period, shall be the basis for calculating the patent restoration term
under paragraph (3) of this subsection.
`(ii) FDA CONSULTATION- The Food and Drug Administration shall be
consulted with respect to the Commissioner's determinations under
subparagraph (A) (i), (ii), and (iii). If there is a dispute concerning
the underlying facts between the patent owner and the Food and Drug
Administration, the Food and Drug Administration shall make the relevant
records of the Administration available to the Commissioner.
`(3) RESTORATION TERM- If the Commissioner determines that the standards
in paragraph (2) have been met for a patent, the term of such patent shall
be restored for a period equal to the regulatory review period as defined in
section 156(g)(1)(B) (taking into account any deduction under paragraph
(2)(B)(i)), without taking into account the 2-year limitation described in
section 156(g)(6)(C), except that--
`(A) the total of the period of the patent term restoration granted
under this section and any patent term extension previously granted under
section 156 shall be subject to the time period limitations described in
section 156(c)(2)-156 (c)(4) and (g)(6)(A); and
`(B) any patent term extension previously granted under section 156
shall be subtracted from the period of the patent term restoration granted
under this subsection.
`(4) INFRINGEMENT- During the period of any restoration granted under
this subsection, the rights derived from a patent the term of which is
restored shall be determined in accordance with sections 156(b) and
271.
`(A) TIME FOR FILING- Any application under this section shall be
filed with the Commissioner within 90 days after the date of enactment of
this section.
`(B) FILING- Upon submission of an application to the Commissioner by
the owner of record of a patent referred to in paragraph (1) or its agent
for a determination in accordance with paragraph (3)--
`(i) the Commissioner shall publish within 30 days after the
submission in the Federal Register a notice of receipt of an application
and make the application available to the public upon
request;
`(ii) any interested party may submit comments on the application
within the 60-day period beginning on the date of publication of the
notice;
`(iii) within 7 days following the expiration of that 60-day period,
the Commissioner shall forward a copy of all comments received to the
applicant, who shall be entitled to submit a response to such comments
to the Commissioner within 45 days after receipt of such
comments;
`(iv) within 30 days following receipt of the applicant's response
to comments or, if there are no such comments, within 30 days following
expiration of the 60-day comment period, the Commissioner shall, in
writing--
`(I) determine whether to grant the application;
and
`(II) make specific findings regarding the criteria set forth in
paragraph (2) (including, where appropriate, findings regarding the
public interest and fairness factors set forth in paragraph (7));
and
`(v) if the Commissioner determines that the standards set forth in
paragraph (2) have been met, the Commissioner shall--
`(I) issue to the applicant a certificate of restoration, under
seal, for the period prescribed under paragraph (3);
and
`(II) record the certificate in the official file of the patent,
which certificate shall be in effect from the date it issues and shall
be considered a part of the original patent.
`(C) PATENT TERM DURING REVIEW- If the term of a patent for which an
application has been submitted under this section would expire before a
determination to issue a certificate of restoration is made under
subparagraph (B), the Commissioner may extend, until such determination is
made (but not to exceed 1 year) the term of the patent if the Commissioner
determines that the patent likely would be eligible for
restoration.
`(D) RECORD AND REVIEW- The Commissioner's determination under
subparagraph (B)(iv) shall be based solely on the record developed under
this subsection. Except as provided in section 141, the Commissioner's
determination shall not be reviewable in any court.
`(6) APPLICATION FEE- The applicant shall pay a fee for an application
made under this subsection which shall be determined in accordance with the
same criteria as the fees established under section 156(h).
`(7) PUBLIC INTEREST AND FAIRNESS- When required to make a determination
under paragraph (2)(A)(iii), the Commissioner shall consider each of the
following factors and shall not rely solely on any single factor:
`(A) Whether grant of the application would result in the public
having no other commercially available alternatives to treat the same
disease or condition as the drug claimed in the patent that is the subject
of the patent term restoration request.
`(B) Whether grant of the application would disserve society's
interest in the availability of innovative drugs at competitive
prices.
`(C) Whether denial of the application would disserve society's
interest in encouraging and rewarding pharmaceutical research and
innovation.
`(D) Whether denial of the application would be unfair to the
applicant, in comparison to others who have experienced the benefits of a
5-year patent restoration under section 156 while experiencing similar
regulatory review delays.
`(E) Whether other manufacturers, before the date of enactment of this
section, have submitted applications under sections 505(b)(2) or (j) of
the Federal Food, Drug, and Cosmetic Act that are sufficiently complete to
permit substantive review and have made substantial investments to
manufacture a generic version of the particular drug that is the subject
of the patent term restoration application, which would not receive the
compensation specified under subsection (e) of the Drug Patent Term
Restoration Review Procedure Act of 1999.'.
(2) TECHNICAL AND CONFORMING AMENDMENT- The table of sections for
chapter 14 of title 35, United States Code, is amended by inserting after
the item relating to section 155A the following:
`155B. Patent term restoration review procedure for certain drug
products.'.
(c) APPEAL OF DETERMINATIONS OF THE COMMISSIONER- Section 141 of title 35,
United States Code, is amended by adding at the end the following: `The
applicant under section 155B, or any aggrieved party that made a submission
commenting on an application under
section 155B, may appeal the determination of the Commissioner under such
section to the United States Court of Appeals for the Federal Circuit.'.
(1) COURT OF APPEALS FOR THE FEDERAL CIRCUIT- Section 1295(a)(4) of
title 28, United States Code, is amended--
(A) in subparagraph (B), by striking `or' after the
semicolon;
(B) in subparagraph (C), by adding `or' after the semicolon;
and
(C) by inserting after subparagraph (C) the following:
`(D) the Commissioner of Patents and Trademarks under section 155B of
title 35;'.
(2) JURISDICTION BASED ON INFRINGEMENT OF PATENT- Section 271(e) of
title 35, United States Code, is amended by adding at the end the
following:
`(5) In any action brought under paragraph (2) involving a patent, the
term of which has been restored under section 155B, the alleged infringer
shall have the right to seek compensation under subsection (e) of the Drug
Patent Term Restoration Review Procedure Act of 1999.'.
(1) IN GENERAL- In the event a person has submitted an application
described in section 505(b)(2) or 505(j) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(b)(2),(j)) for a drug product covered by a
patent for which a patent term restoration was provided under section 155B
of title 35, United States Code (as added by subsection (a)(1)) and such
application has been found by the Food and Drug Administration on or before
the date of the enactment of this section to be sufficiently complete to
permit substantive review, such person shall be entitled to compensation of
$2,000,000 by the patent owner. Any holder of a Type II Drug Master File
that has permitted a reference to its Type II Drug Master File to be made in
such application shall be entitled to compensation of $1,000,000 by the
patent owner.
(2) LIMITS ON LIABILITY- A patent owner shall not be required to make
under paragraph (1) payments exceeding--
(A) $10,000,000 to persons submitting applications described in such
paragraph, or
(B) $5,000,000 to holders of Type II Drug Master Files.
If the aggregate limits are insufficient to pay the applicants or
holders the full amounts specified in paragraph (1), each such applicant or
holder shall be paid its per capita share of the aggregate liability imposed
by paragraph (1) upon the patent holder.
(f) EFFECT OF FILING OF ABBREVIATED APPLICATIONS- The fact that 1 or more
abbreviated applications have been filed under section 505 (b) or (j) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355 (b) or (j)) for approval
of a drug product, which is covered by a patent that is the subject of an
application for term restoration under this section, shall not preclude the
grant of such term restoration.
(g) REPORT TO CONGRESS- Not later than 1 year after the effective date of
this section, the Commissioner of Patents and Trademarks shall--
(1) submit to Congress a report evaluating the patent term restoration
review procedure established under this section; and
(2) include in such report a recommendation whether Congress should
consider establishing such a patent term restoration review procedure for
other patents.
(h) EFFECTIVE DATE- This section shall take effect on the date of
enactment of this section and an owner of record of a patent referred to under
section 155B(b)(1) of title 35, United States Code (as added by this section);
or an agent of the owner shall be immediately eligible on such a date to
submit an application to the Commissioner for a determination in accordance
with subsection (b)(3) of such section.
SEC. 2. AMENDMENTS TO THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.
(a) LIMITATION ON USE OF PATENTS TO PREVENT ANDA APPROVAL-
(1) APPLICATION- Section 505(b)(2) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(b)(2)) is amended by adding at the end the
following:
`For an approved product claimed in a patent, the term of which has been
restored pursuant to section 155B of title 35, United States Code, the
certification required by subparagraph (A) is limited to any patent that
claims an active ingredient, including any salt or ester of the active
ingredient, of the approved product, alone or in combination with another
active ingredient.'.
(2) ABBREVIATED APPLICATION- Section 505(j)(2)(A) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355(j)(2)(A)) is amended by adding at the
end the following:
`For an approved product claimed in a patent, the term of which has been
restored pursuant to section 155B of title 35, United States Code, the
certification required by clause (vii) is limited to any patent that claims an
active ingredient, including any salt or ester of the active ingredient, of
the approved product, alone or in combination with another active
ingredient.'.
(b) EXCLUSIVITY FOR GENERIC DRUG- Section 505(j)(5)(B)(iv) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(5)(B)(iv)) is amended by
inserting after `containing such certification' the following: `and for which
an action for infringement of a patent which is the subject of such a
certification has been brought before the expiration of 45 days from the date
of the notice provided under paragraph (2)(B)(i) is received'.
END